Trafalgar International (GCAN) Receivables (2020 - 2021)
Greater Cannabis Company (GCAN) posted quarterly Receivables of $36750.0 for Q3 2021, up 55.89% year-over-year from $23575.0 in Q3 2020, and little changed quarter-over-quarter from $36750.0 in Q2 2021.
Trafalgar International (GCAN) Receivables (2020 - 2021) Analysis & Trends
Greater Cannabis Company's Receivables history runs 2 years deep, the most recent figure standing at $36750.0 for Q3 2021.
- In Q3 2021, Receivables rose 55.89% year-over-year to $36750.0; the TTM figure through Sep 2021 stood at $36750.0 (up 55.89% YoY), while the FY2020 annual figure was $36750.0, changed N/A from the prior year.
- Receivables for Q3 2021 stood at $36750.0, roughly flat from $36750.0 in the prior quarter.
- The five-year high for Receivables was $36750.0 in Q4 2020, with the low at $23575.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 36,750.00 |
| Jun 30, 2021 | 36,750.00 |
| Mar 31, 2021 | 36,750.00 |
| Dec 31, 2020 | 36,750.00 |
| Sep 30, 2020 | 23,575.00 |
| Jun 30, 2020 | 23,575.00 |